Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
Completed · Phase 2
Conditions studied: Prostate Cancer
In brief
The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men with ER positive Breast Cancer.
Key facts
- Study ID
- NCT02130700
- Run by
- Innocrin Pharmaceutical
- People needed
- 17
- Starts
- 2014-04-01
- Expected to finish
- 2017-11-01
- Last updated by the study team
- 2018-05-07
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- National Institutes of Health, National Cancer Institute — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.